The similar results were also obtained by Miyazaki et al. (2002) who demonstrated that after intervention type 2 diabetic patients with pioglitazone (another kind of TZD) for 4 months, they had decreased visceral fat area and improved hepatic and peripheral insulin sensitivity. This evidence concerns the gene INS and type 2 diabetes mellitus.